| Budget Amount *help |
¥18,200,000 (Direct Cost: ¥14,000,000、Indirect Cost: ¥4,200,000)
Fiscal Year 2014: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥9,620,000 (Direct Cost: ¥7,400,000、Indirect Cost: ¥2,220,000)
|
|---|
| Outline of Final Research Achievements |
To elucidate mechanism of targeted drug resistance in metastatic lesions, we established in vivo imaging models for pleural carcinomatosis and bone/brain metastases, which are resistant to targeted drugs, of EGFR mutant or ALK fusion positive lung cancer cell lines. We found that resistant tumors consist of a heterogeneous mixture of functionally distinct cancer cells with different resistant mechanisms. Moreover, our observation indicated that we should be careful for toxicity of combined therapy which overcome targeted drug resistance caused by multiple mechanisms.
|
